Journal of Immunology Research

Journal of Immunology Research / 2018 / Article
Special Issue

Regulation of Inflammation in Autoimmune Diseases

View this Special Issue

Review Article | Open Access

Volume 2018 |Article ID 3491269 | 13 pages |

TNIP1 in Autoimmune Diseases: Regulation of Toll-like Receptor Signaling

Academic Editor: Cinzia Ciccacci
Received08 Jun 2018
Accepted17 Sep 2018
Published03 Oct 2018


TNIP1 protein is increasingly being recognized as a key repressor of inflammatory signaling and a potential factor in multiple autoimmune diseases. In addition to earlier foundational reports of TNIP1 SNPs in human autoimmune diseases and TNIP1 protein-protein interaction with receptor regulating proteins, more recent studies have identified new potential interaction partners and signaling pathways likely modulated by TNIP1. Subdomains within the TNIP1 protein as well as how they interact with ubiquitin have not only been mapped but inflammatory cell- and tissue-specific consequences subsequent to their defective function are being recognized and related to human disease states such as lupus, scleroderma, and psoriasis. In this review, we emphasize receptor signaling complexes and regulation of cytoplasmic signaling steps downstream of TLR given their association with some of the same autoimmune diseases where TNIP1 has been implicated. TNIP1 dysfunction or deficiency may predispose healthy cells to the inflammatory response to otherwise innocuous TLR ligand exposure. The recognition of the anti-inflammatory roles of TNIP1 and improved integrated understanding of its physical and functional association with other signaling pathway proteins may position TNIP1 as a candidate target for the design and/or testing of next-generation anti-inflammatory therapeutics.

1. Introduction

Autoimmune diseases are chronic, relapsing disorders characterized by immune dysregulation featuring loss of tolerance, generation of autoreactive T and B cells, circulating autoantibodies, and chronic inflammation. For those pathologies with genetic variant or expression level differences in the anti-inflammatory protein TNIP1 (TNFα-induced protein 3- (TNFAIP3-) interacting protein 1), this can be associated with increased immune cell activation and infiltration leading to tissue-specific defects including but not limited to loss of serum protein to the urine (lupus nephritis), failure of the epidermal barrier (psoriasis), or diminished lung function (systemic sclerosis). These cases occur in the larger cohort of autoimmune diseases. When considered together, these include about 30 diseases with an estimated prevalence of ~9% which in turn is modulated by gender, age, and ethnicity [1, 2]. Compounding these numbers, the incidence of autoimmune disease in westernized countries appears to be increasing [3, 4]. Costing over 100 billion dollars in healthcare expenses and as a leading cause of morbidity especially in women under sixty-five [5], autoimmune diseases are devastating to patients. While major histocompatibility complex (MHC) genes [6] are central to many of these diseases, environmental factors including diet, UV irradiation, drug exposure, and infectious agents [3, 7] as well as numerous non-MHC susceptibility loci [8] are being recognized as players in the complex etiology of autoimmune diseases. Treatment for autoimmune disease has revolved around managing immune-mediated hyperactivity by dampening inflammatory responses and immune cell proliferation. However, this approach leaves patients vulnerable to opportunistic infections which can be life-threatening [9]. Thus, there is a continuous need to discover and define potential inflammatory signal suppressors, some of which are present in those disease-associated non-MHC loci, whose deficiency or dysfunction could contribute to autoimmune disease. There is significant building evidence that TNIP1 (also known as ABIN-1, Naf1, and VAN) [1012] fits this description. As a suppressor of inflammatory signaling downstream of Toll-like receptors (TLRs), TNIP1 could play a pivotal role in specific autoimmune diseases. TNIP1 genetic association with certain autoimmune diseases and its negative regulation of inflammatory signaling will be explored in this review. Mechanistic understanding of signaling regulators such as TNIP1 could lead to them becoming therapeutic targets.

2. TNIP1 (TNFAIP3-Interacting Protein 1)

2.1. Genome-Wide Association and Expression-Regulating Studies: Implications in Inflammatory Disease

Over the last decade, TNIP1 has been reported among the highest scoring non-MHC genes across multiple genome-wide association studies (GWAS), spanning multiple populations and diseases including psoriatic arthritis [1316], systemic sclerosis [17, 18], systemic lupus erythematosus [1924], and psoriasis [2527]. TNIP1 sequence variations (single nucleotide polymorphisms (SNPs)) in these populations implicate it in what are nevertheless diseases with likely multiple genetic and environmental factors. However, even with the identification of the heritability of autoimmune disease through twin and familial studies [28, 29], no single gene has been established as the culprit. In common with other disease-associated SNPs [30], those identified for TNIP1 are more likely intergenic and intronic [16, 18, 23, 26]. In general, such nucleotide changes may lessen transcription factor binding at a gene promoter, mRNA processing efficiency, and/or mRNA half-life, leading to decreased protein [31]. Additionally, two microRNAs, miR-517a/c, targeting TNIP1 message, significantly decrease TNIP1 protein levels when transfected in HEK293 cells [32]. In contrast, an apparently phenotypically silent SNP in the TNIP1 mRNA 3’UTR can reduce the negative effect of miR-517a/c. Together, these studies suggest multiple processing and turnover events that contribute to TNIP1 message abundance where those leading to decreased steady-state levels would allow for greater activation of NF-B and hyperresponsiveness to TLR stimuli. While such laboratory investigations functionally link TNIP1 protein levels to the regulation of inflammatory pathway signaling, more study is required to determine what expression steps (mRNA processing, mRNA and protein half-life) are normally or pathologically contributing to these levels.

Parallel to genetic studies, expression microarray experiments have implicated TNIP1 in disease pathogenesis although seemingly paradoxically as its increased transcription was reported for the inflammatory diseases of rheumatoid arthritis and psoriasis [26, 33]. Increased TNIP1 transcription also occurs in B cells following the occupation of cell surface CD40 [34]. These results are actually consistent with positive regulation of TNIP1 expression by NF-κB and its corresponding binding sites in the human TNIP1 gene promoter [35, 36] and the activation of B cell NF-κB post CD40 occupation [37]. However, such mRNA increases are not universally predictive of disease state protein levels as Chen et al. showed decreased TNIP1 protein in psoriatic plaques [38] consistent with loss of its repressive effect and promotion of inflammatory skin disease. In complementary studies, we showed overexpression [39] of TNIP1 protein in HaCaT keratinocytes that led to decreased expression of multiple inflammation-associated genes including interleukin (IL)-6 while TNIP1 reduction [40] promoted expression of numerous cytokine and chemokine genes. Together, these studies demonstrate TNIP1 as an important inflammatory signal response and regulator gene in diverse cell types. It also corroborates the spontaneous systemic autoimmunity observed with TNIP1 deficiency or loss-of-function mutations characterized in part by increased NF-κB activation [41, 42].

2.2. Cellular Location and Role in Cell Activation

TNIP1 is found ubiquitously throughout the body in both the nuclear and cytoplasmic compartments of cells [43] where it has been implicated as a mediator of multiple pathways. For example, it functions in the nucleus where it can act as a corepressor of ligand-bound retinoic acid receptors (RARs) [44] and peroxisome proliferator acid receptors (PPARs) [45]. TNIP1 is found in the cytoplasm as well where it is able to interact with HIV-encoded proteins nef [11] and matrix [12], modulate signaling downstream of epidermal growth factor receptor (EGFR) via interactions with ERK2 [46], and interact with the ubiquitin-editing protein TNFAIP3 (alias A20 with roles in inflammation and autoimmunity that have been reviewed elsewhere [47]). The interaction between A20 and TNIP1, mediated by the ABIN-homology domain 1 (AHD1) domain of TNIP1 [48], promotes negative regulation of MAPK activation as well as NF-κB-mediated gene transcription downstream of TNFR and TLRs [10, 42]. TNIP1 function as a negative modulator downstream of select cell membrane receptors and its loss or dysfunction could lead to initiation and perpetuation of an autoimmune phenotype.

2.3. Identification of Ubiquitin-Sensing Domain: Importance in Mediating Inflammation

TNIP1 does not possess enzymatic activity and is thought to influence intracellular signaling through association with its binding partner ubiquitin-editing enzyme A20 (alias TNFAIP3) [49, 50]. The TNIP1-A20 complex then utilizes the ubiquitin-binding domain of ABIN and NEMO (UBAN, alias AHD2) within TNIP1 for the recognition of linear (Met1) and K62-linked polyubiquitin chains [48]. The homologous UBAN domains also occur in TNIP2, TNIP3, and optineurin with a presumed similar role in the control of cytoplasmic signaling. Expected UBAN functionality stems from earlier reports that polyubiquitin binding by NEMO was a key to NF-κB-mediated transcription downstream of TNFα [5153]. Current understanding of polyubiquitin in signaling downstream of TLRs (among other receptors) describes two roles of polyubiquitin. Firstly, polyubiquitin acts as an activator of kinases by inducing conformational changes in those enzymes when bound (e.g., TAB2/TAB3 binding K63-ubiquitin then activating TAK1 within the TAB2/3/TAK1 complex). Secondly, polyubiquitin may act as a scaffold for colocalization of different complexes associated with TLR activation (e.g., TAB2/TAB3/TAK1 complex activation of the NEMO/IKKα/β complex through K63/Met1 hybrid polyubiquitin chains) [54] (Figure 1(a)). These interactions promote eventual phosphorylation of targets including MAPKs and the inhibitor of NF-kappa Bα (IκBα) [55]. Initial studies described TNIP1 as capable of increasing the rate of A20-mediated removal of polyubiquitin; with decreased expression of TNIP1 via siRNA knockdown, the rate of A20-mediated de-ubiquitination of NEMO was decreased [56]. However, more recently it has been shown that knock-in mice with A20 mutants featuring no de-ubiquitinase activity presented phenotypically normal and showed normal responsiveness to both TLR (LPS) and TNFR (TNF) ligands [57]. TNIP1 has also been shown to function in signal repression even in the absence of A20 [41, 58]. In the latter study, floxed alleles of A20 and TNIP1 (ABIN-1) in a villin-ER/Cre + mouse system were used to examine intestinal epithelial cell responses to tamoxifen-induced TNIP1 and/or A20 deletion. With the loss of A20 alone, TNIP1 seems to function independently and provide some compensatory response limiting the extensive mortality observed with the dual A20/TNIP1 knockout. As those investigators concluded, there appears to be a “synergistic, though asymmetric, relationship” between A20 and TNIP1 (ABIN-1) [58]. This points to TNIP1 promoting repression of signaling not only due to increased A20 ubiquitin-editing activity but also due to a potential mechanism where TNIP1 disrupts scaffold formation dependent on polyubiquitination and complex formation through binding and prevention of protein-protein interactions (Figures 1(b) and 1(c)).

Aside from NEMO, other targets of polyubiquitin downstream of TLR activation have been described as negatively regulated by TNIP1 including TANK-binding kinase 1 (TBK1) [59], receptor-interacting serine/threonine kinase 1 (RIP1 or RIPK1) [41], and interleukin-1 receptor-associated kinase 1 (IRAK1) [42]. Association of TNIP1 with IRAK1 was abolished with a loss of function mutation in its UBAN domain despite the presence of TLR4 agonist LPS. Loss of UBAN function promoted increased IRF3-mediated transcription downstream of K63 ubiquitin target TBK1 in the presence of TLR3 agonist. RIP1, another TNIP1 interaction partner, participates in signaling downstream of both TLR and TNF receptors, mediating inflammatory responses [60] and cell-death signals [61]. Loss of TNIP1 UBAN functionality (QQ477EE mutation) prevents this interaction and associated regulation of programmed cell death (PCD) [41]. More recently, RIP1 regulation by TNIP1 has been determined to be dependent on both Met1 ubiquitination and K63 ubiquitination, ultimately promoting de-ubiquitination of RIP1 by a more stable A20 [62]. The importance and widespread effects of TNIP1 repression on inflammatory pathways are clearly based on diverse targets of TNIP1-mediated regulation described above. Beyond inflammatory signaling pathways, polyubiquitination affects structure, function, and stability of almost innumerable proteins and thus the related biological consequences of those proteins [63]. We suggest that future studies of TNIP1 interacting with these ubiquitinated proteins are likely to reveal the new and wide-reaching significance of the TNIP1 protein.

3. Toll-like Receptors (TLR)

3.1. Structure and Role in Cell Activation

Following exposure to microbes, cellular mechanisms are activated to recognize these foreign pathogens and eliminate them. These mechanisms rely on both innate and adaptive immunity through recognition by antigen-specific and nonspecific receptors. During innate immunity, foreign pathogens are recognized by pattern-recognition receptors (PRRs) which include Toll-like receptors, a family of type 1 transmembrane receptors capable of forming hetero- or homodimers on the cell membrane (TLR1, 2, 4, 5, and 6) and intracellularly (TLR3, 7, 8, and 9) within endosomes, lysosomes, or the endoplasmic reticulum [64]. TLRs are commonly expressed on sentinel inflammatory cells such as macrophages and dendritic cells as well as on nonimmune cells such as fibroblasts and epithelial cells [65]. As a component of the innate immune system, TLRs allow for a rapid response to environmental triggers in defense against microbial infections [66]. These receptors are capable of recognizing environmental cues, known as pathogen-associated molecular patterns (PAMPs), associated with foreign pathogens (bacteria, fungi, parasites, and viruses). TLRs are also capable of recognizing host-derived endogenous ligands referred to as damage-associated molecular patterns (DAMPs) which include free fatty acids, oxidized lipids as well as heat-shock proteins (HSP60 and HSP70) and extracellular membrane (ECM) components released during cell injury and apoptosis [64, 67]. PAMPs recognized by TLRs can be separated into two types based on whether they are sensed externally (e.g., bacterial lipids and lipopolysaccharide (LPS) and flagellin) or within intracellular compartments (e.g., nucleic acids including viral dsRNA, ssRNA, and CpG-DNA).

3.2. Key Components and Divergent Pathways

Common to TLR is an extracellular domain featuring leucine-rich repeats (LRRs), which allow for diversity in recognizing agonists, and a cytoplasmic Toll/IL-1 receptor (TIR) domain involved in adaptor protein recruitment associated with receptor activation/dimerization [68]. With binding of PAMP or DAMP by the LRR domain, downstream consequences include secretion of chemokines, proinflammatory cytokines, and/or type I/II interferons. This is mediated by a number of recruited TIR domain-containing proteins (Figure 1(a)) including myeloid differentiation primary-response protein 88 (MyD88), TIR-domain-containing adaptor protein inducing β interferon (TRIF), TIR-domain-containing adaptor molecule (TIRAP), or TIR-domain-containing adaptor molecule (TRAM). Excluding TLR3, all other TLR initiate signaling by recruiting MyD88 (with TLR1, 2, 4, and 6 recruiting intermediate adaptor protein TIRAP along with MyD88) [69]. TLR3 acts through recruitment of TRIF, with TLR3 requiring secondary adaptor protein TRAM. Although shared signaling events such as phosphorylation and ubiquitination occur, there is a divergence in the use of receptor adaptor protein MyD88.

3.2.1. MyD88-Dependent Signaling Pathway

Loss of MyD88 expression has been associated with decreased ability to mount an immunological response to certain types of infections in mice and humans [7072]. MyD88 acts as a key bridge between the death domain (DD) containing IL-1R-associated kinase (IRAK) 4 and the TIR domain of TLRs. IRAK-4, a serine/threonine kinase, drives signaling by promoting the activation of two other IRAK proteins, IRAK-1 and IRAK-2, forming what is called the Myddosome [73]. Due to its importance in signaling, efforts have been ongoing to target IRAK-4 therapeutically [74]. With activation of IRAK-1 and IRAK-2, the IRAK proteins dissociate and form a complex TNFR-associated factor 6 (TRAF6) which acts as an E3 ligase in concert with E2 ubiquitin-conjugating enzyme complex UBC13 and UEV1A, promoting auto-K63-linked ubiquitination and activation of mitogen-activated protein kinase kinase kinase 7 (TAK1). TAK1 plays a central role in the activation of both canonical pathways resulting in NF-κB-mediated transcription and noncanonical pathways leading to AP-1-mediated transcription via ERK/JNK/P38 [69]. TAK1 activation is believed to occur following TAK1 complex formation with TAK1-binding protein 1 (TAB1), TAB2, and TAB3. This complex formation (Figure 1(a)) is dependent on TAB2/3 interaction with K63-linked polyubiquitin [75]. Activation of TAK1 promotes further activation of the IκB kinase (IKKβ) and MAP kinase kinase 6. IKKβ is associated with IKKα and NEMO (known as IKKγ) and leads to phosphorylation, K48-linked ubiquitination of NF-κB inhibitor alpha (IκBα), and proteasomal degradation freeing NF-κB subunits to translocate into the nucleus. NEMO association with linear polyubiquitin via the linear ubiquitin chain assembly complex (LUBAC) is a key to the eventual IκBα degradation via the IKK complex (IKKα, IKKβ, NEMO) [76]. Compartmentalized TLR7 and 9 are distinct from other MyD88-dependent TLRs in that they can promote interferon secretion (mainly IFNα), making them powerful tools against invading microbe-associated nucleic acids. This occurs through IRF7 activation by IRAK-1 phosphorylation in a MyD88, IRAK-1, TRAF3, IKKα, and IRK7 complex [77].

3.2.2. Non-MyD88-Dependent Signaling Pathway

TLR3 signaling was reported as one of the two TLRs sensitive to TRIF-deficiency in mice [78]. MyD88 deficiency in bone marrow-derived macrophages (BMDM) promoted increased TLR3-mediated cytokine secretion [79]. Through TRIF, TLR3 is capable of inducing TRAF6-mediated gene expression, as in MyD88-dependent signaling, by promoting K63-linked ubiquitination of RIP1 (Figure 1(a)), with pellino1 being a key in the activation of RIP1 [80]. RIP1 can then promote activation of the TAK1 complex and subsequent events leading to IκBα degradation. TRAF3, an E3 ligase like TRAF6, promotes TRAF6-independent [81] IRF3 phosphorylation by ubiquitination of TANK-binding kinase 1 (TBK1) and formation of IKKε/TBK1 complex. Activated IRF3 forms a dimer and enters the nucleus where it promotes type I IFNs secretion.

4. TNIP1 in Inflammation and Disease

With all the unknown factors remaining in regard to the initiation of autoimmune or hyperinflammatory conditions, it is clear that there are multiple simultaneous factors contributing to these diseases. One such factor is a genetic component such as DNA sequence variants found in association with specific disease states. As presented below, TNIP1 is an oft-cited gene in GWAS studies with SNPs in certain populations suffering from systemic lupus erythematosus, psoriasis, and systemic sclerosis [1316]. For recent consideration of possible genetic association of TNIP1 with other autoimmune diseases such as Sjögren syndrome and psoriatic arthritis, the reader is directed to [82, 83].

4.1. Systemic Lupus Erythematosus

In SLE, the loss of immune tolerance and with it, triggering of autoreactive T and B cells appears as a key to the development and progression of the disease state which is compounded by genetic predispositions and exposure to environmental risk factors. Plasmacytoid dendritic cells (pDCs) are antigen presenting cells (APC) capable of sensing ssRNA and unmethylated CpG DNA sequences through endosomal TLR7 and 9, respectively [84]. When activated by these ligands, pDCs produce high levels of type I interferons (IFNα/β) (Figure 2). IFNα has been implicated in many clinical manifestations of SLE [85] and, interestingly, when used therapeutically, IFNα has been shown to induce a SLE-like phenotype [86]. pDC activation by host DAMPs is avoided as these cells can distinguish between microbial and self-nucleic acids [87]. However, such tolerance is believed to be compromised with generation and accumulation of increased protein and nucleic acid associated DAMPs from apoptosis-associated proteases and nucleases. Circulating pDCs internalize these new DAMPS with complexes formed with IgG leading to potent activation of endosomal TLR7 and 9 [88, 89] and increased IFNα production [9092]. TLR7 null mice were partially protected from similar effects due to decreased pDC responsiveness and in-turn reduced IFNα and IL-6 expression [93]. Conversely, increased expression of TLR7 in transgenic mice overexpressing TLR7 spontaneously developed fatal and acute immune dysregulation and autoimmunity [94]. With these observations in human SLE patients and mice experiments, the importance of TLR activation in the progression of the SLE phenotype becomes clear.

The GWAS correlation of TNIP1 sequence variants to several autoimmune diseases [1719, 22, 26], for example, and evidence of NF-κB signaling possibly under TNIP1 control post-TLR signaling [10, 19, 26, 50, 95] provided rationale for investigating SLE-like characteristics in knockout or mutant knock-in mouse models, respectively, with missing or dysfunctional TNIP1 protein. Such mouse experimental systems set the stage to study TNIP1 functional differences underlying likely contribution to phenotypes of the whole animal activated immune systems.

To address the high proportion of late embryonic Tnip1 −/− lethality seen earlier [41], Zhou and colleagues crossed 129S2 ES-cell-derived Tnip1 +/− mice to a C57BL/6 background [96]. Although the influence of mouse genetic strain remains unresolved, there is an increase in phenotypically normal live-born pups; however, by four months of age, these mice develop a wasting syndrome along with leukocyte infiltration of kidneys, liver, and lungs. Echoing a SLE phenotype, there are increased levels of autoreactive antibodies against dsDNA and development of significant glomerulonephritis which are not rescued by a TNFR null background. In contrast to the expected NF-κB-mediated transcriptional increases, CpG occupation of TLR9 in Tnip1 −/− bone marrow-derived macrophages [96], strikingly activates C/EBPβ-regulated promoters including that of proinflammatory SLE severity-correlating S100A8 [97]. Strikingly, knock-in mice engineered with a Tnip1 mutant [D485N] [42] defective in binding both K63-linked and linear polyubiquitin chains (see UBAN section above), and therefore with predicted increased TNFα sensitivity, are born at the same size and frequency of Tnip1 +/+ mice. These Tnip1 [D485N] mice show age-associated autoimmunity marked by enlarged spleens and circulating levels of antinuclear and anti-DNA antibodies, the latter consistent with the development of severe glomerulonephritis [42]. For cultured cells, Tnip1 [D485N] MEF do not display TNFα-enhanced activation of MAPKs but do show exaggerated responses via activation of JNK, p38, and NF-κB in B cells and BMDC exposed to several TLR ligands including LPS (TLR4), lipoteichoic acid (TLR2/6), and R848 (TLR7). Along these lines, when challenged with TNFα, human immortalized kidney podocyte cells recombinantly expressing the human ubiquitin-binding deficient homologue mutant [D472N] but not human wildtype TNIP1 [98] have increased expression of numerous chemokine genes echoing increased NF-κB-regulated inflammatory signaling in SLE and glomerulonephritis patient kidney samples. Further complementary studies of both receptors’ cytoplasmic activation steps should help determine the full range of TNIP1 protein suppressive capabilities. For instance, in Tnip1 [D485N] mice, a lupus nephritis-like presentation is prevented when crossed to backgrounds with catalytically inactive signaling proteins downstream of TLRs such as IRAK-1 or IRAK-4 [99].

The range and sometimes divergence of TNIP1 effects on postreceptor signaling interpreted from overexpression studies, whole animal null or knock-in, and cell-specific deletion [100103] may be reflecting its as yet uncharacterized quantitative and/or qualitative characteristics. These may arise from mouse strain influences, varying expression levels of TNIP1 protein and/or its varying interacting partners in different cells [11, 43, 104, 105] and cell- or organ-specific sensitivity to various cytokine and PAMP/DAMP receptor agonists. Further study in these complementary systems will help to advance our understanding of a role for TNIP1 in SLE pathology. Reconciling such differences will be central to considering any possible therapeutic targeting of TNIP1’s repression of the multiple signaling pathways downstream of distinct membrane receptors.

4.2. Psoriasis

Psoriasis is a chronic skin disorder affecting about 2% of people in the United States, most commonly manifested as plaque psoriasis (psoriasis vulgaris) and accounting for about 90% of all cases. Psoriasis is an immune-mediated disorder that manifests in the skin or joints, which is influenced by both environmental and genetic components [106]and characterized by aberrations in the skin epithelium specifically hyperproliferation in the epidermis and hyperactive keratinocytes with increased mitotic rates. This increased replication of keratinocytes results in poor maturation leading to incomplete cornification observed clinically as poor barrier function and histologically as retained nuclei in the stratum corneum (parakeratosis) and thickening of the epidermis (acanthosis) with elongated rete ridges. Immune infiltration is a hallmark of psoriasis featuring increased dendritic cells (DCs) and macrophages in the dermis and neutrophils in the epidermis. T cells are found in increased numbers in both with higher numbers of Th1, Th17, and Th22-polarized T cells [107]. Family-based linkage studies have established the strongest genetic links to psoriasis with the class 1 region of the MHC cluster near the HLA-Cw6 allele. These studies are consistent with GWAS studies which have identified the same HLA region as well as other genes including IL-23R, IL-12β (p40), and TNIP1 [26, 108, 109].

Differential TNIP1 expression in psoriatic patients versus healthy controls has been described previously [26] with observed increases in mRNA expression coupled with a 2-fold decrease in protein expression in the patients [38]. To establish models of TNIP1 loss in psoriasis, various cell culture models and in vivo approaches have been taken. Chen et al. used TNIP1 shRNA injection to promote local TNIP1 deficiency in a region of the skin followed by topical exposure to the TLR7 agonist imiquimod (IMQ), which is a compound used frequently to promote psoriasis-like phenotype in mice [110]. In these mice, tissue with reduced TNIP1 had a significantly higher overall psoriasis disease score, as compared to wild-type IMQ treated. This included increased raised, scaly, erythematous plaques marked by epidermal thickening, hyperkeratosis, and parakeratosis. These characteristics closely mimic the presentation of psoriasis in human patients. Using a TNIP1 null line challenged with IMQ, Ippagunta et al. demonstrated that skin inflammation has more characteristic of psoriasis than atopic eczema via comparison with microarray analysis of corresponding human disease samples [111]. These mouse models suggest that human disease may be a combination of genetic predisposition (TNIP1 SNPs) coupled with environmental assault (TLR ligands).

Psoriasis is believed to be a disease of both epithelial cell dysfunction coupled with immune cell over-activation. This mechanism centers around T Helper (Th) 17 cells which secrete IL-17α and IL-22, potent inducers of keratinocyte activation and proliferation [112]. Interestingly, cultured cells experimentally exposed to IL-17a showed increased rates of TNIP1 protein degradation [113]. IL-23 secreted by activated DCs promotes the expansion of already differentiated Th17 cells (from naive CD4+ T cells in the presence of TGFβ, IL-1β, and IL-6) [114, 115]. Increased keratinocyte activation promotes increased chemokine, cytokine, and antimicrobial peptide secretion resulting in increased DC activation leading to increased IL-23 which promotes Th17 proliferation leading to subsequent keratinocyte activation and completing the cycle (Figure 2) [112, 116]. Most of the mechanistic understanding of psoriasis is in the propagation and worsening of the disease state. Still lacking is an understanding of what promotes initiation of the disease. One proposed mechanism for initiation begins with external stimuli such as microbial infections or physical trauma leading to RNA/DNA-LL-37 (antimicrobial peptide) complex formation and internalization by circulating pDCs, where it acts as an agonist for endosomal TLRs 7 and 9, resulting in IFNα secretion. IFNα expression promotes DC activation which would allow for antigen presentation, T cell differentiation, etc. [106]. Under normal conditions, this would lead to an appropriate immune response and activation. Under conditions with genetic polymorphisms in PSORS1, IL-23R, A20, TNIP1, and/or other genes implicated in association studies, this response may become exaggerated. Our group and others have shown that TNIP1 reduction alone does not promote a chronic hyperinflammatory state [38, 40]. However, when coupled with an external stimulus, there is a clear exaggerated response [38, 40]. Thus, keratinocytes deficient for TNIP1 may contribute to hyperactivation of local immune responses when exposed to TLR environment- or skin cell-derived agonists.

For studies of cell signaling in a psoriasis-relevant model, Callahan et al. used CD11c-Cre LoxP system to engineer a TNIP1 DC-specific knockout [103]. When exposed to TLR ligands, these mice developed splenomegaly and lymphadenopathy with an accumulation of myeloid cells suggesting a systemic activation of the immune system, as previously observed in the whole mouse TNIP1 knockout [41, 96]. Topical exposure to IMQ, a TLR7 ligand, instigated a higher overall psoriasis phenotype score (higher levels of epidermal hyperplasia, hypogranulosis, hyperparakeratosis, and epidermal neutrophil infiltration) compared to control animals. BMDC from these mice when treated with TLR ligands (IMQ, LPS) showed increased secretion of immune cytokines including IL-23, an interleukin considered critical in psoriasis development due to its ability to induce Th17 cell proliferation. Ippagunta et al., confirmed this finding using BMDC from TNIP1 knockout mice. They also demonstrated the importance of TNIP-mediated regulation of TLRs in T cell and nonimmune cell (keratinocytes, fibroblasts) mediated immunity [111]. Using keratinocyte-specific TNIP1 knockout mice, these investigators demonstrated that keratinocyte-initiated immune signaling, through the IMQ-induced expression of numerous cytokines, antimicrobial peptides, and chemokines, can induce psoriasis-like disease. Thus, for several immune and nonimmune cell types, these studies demonstrate the importance of TNIP1 control over internal signaling pathways and also external paracrine interactions among them (Figure 2).

4.3. Systemic Sclerosis (Scleroderma)

The etiology, clinical pathology, and cell biology of systemic sclerosis (SSc) lead to multicell signaling interactions coming together to trigger micro-vascular damage, inflammatory signal production, and cardiac, pulmonary, and dermal fibrotic responses [117]. Prevalence of SSc cases (~14 per 100,000 persons) can vary significantly as there appear to be significant disease subtype, gender, age, race, and ethnic group qualifiers [118, 119]. While thickening, hardening, and tightening of the skin are classic and common in most presentations, it is a decline in internal organ function, such as the lungs and gastrointestinal tract from local vasculopathy and excess extracellular matrix deposition that most significantly promotes disease morbidity and mortality [120122].

Familial and epidemiologic studies provide clear genetic associations between SSc and HLA [117, 123125] and non-HLA loci which are often in-common for other autoimmune pathologies [126]. Three separate reports have added TNIP1 to these non-HLA loci [17, 18, 127]. Like many pathology-associated SNPs, TNIP1 sequence variations associated with SSc to date are in noncoding sequences (intronic and potential genetic expression-regulatory regions). Interestingly, three other proteins with proven physical interaction with and/or signaling regulatory control by TNIP1 are implicated in SSc by GWAS reports suggesting their mutual contribution to relevant pathways. A PPARγ SNP [128, 129] is associated with SSc, and we previously established TNIP1 as a nuclear corepressor of PPARα and γ activity [45]. At least three SNPs of the TNIP1 cytoplasmic binding partner TNFAIP3 (A20) carry an increase for susceptibility to SSc [117, 130132]. Additionally, the SNP resulting in an amino acid substitution (Pro631His) in TLR2 is associated with increased progression of SSc-associated pulmonary arterial hypertension [133, 134]. Thus, even when not a genetic variant itself, signal control/initiation node (s) (TNFAIP3, TLR, and PPAR) impacted by TNIP1 may be contributory to SSc.

In addition to genetic sequence variants for the TNIP1 pathway-associated proteins TLR and TNFAIP3, several functional and expression levels studies have linked their normal counterparts to SSc. In part because of the relative clinical accessibility of cutaneous biopsies compared to internal organ sampling, these studies may be biased to dermal fibroblast characteristics. Nevertheless, several studies have found expression of TLR9 [135] and TLR4 as well as endogenous ligands for the latter [136138] increased in SSc lesion specimens. Fibroblasts cultured from SSc skin biopsy explants displayed a degree of TLR3 expression induction by interferon greater than control cells. Additionally, SSc lesion-derived dermal fibroblasts, under otherwise standard culture, demonstrated a sensitivity to the TLR3 synthetic ligand poly (I:C) greater than control fibroblasts [139]. The full spectrum of TLR in multiple cell types and their demonstrated or possible involvement in SSc has been comprehensively reviewed by Fullard, Bhattacharyya, and colleagues [136, 140]. Thus, deficiency or dysfunction in TNIP1-adjacent proteins such as its functional partner TNFAIP3 (A20) or excess upstream signaling initiated by sensors of innate immune system activity such as TLR may overwhelm the signaling-dampening abilities of TNIP1 [134, 141].

Intriguingly, following up on TNIP1 SSc SNPs [18], Allanore and colleagues reported that compared to skin samples derived from age- and sex-matched healthy controls, the TNIP1 protein was decreased in SSc lesional skin. Separate expression array studies [142] support reduced TNIP1 in lesional skin compared to patient uninvolved skin. Cultured SSc patient dermal fibroblasts [18] have reduced TNIP1 mRNA and protein. These SSc fibroblasts produced elevated levels of collagen in response to cytokine challenge (TNF). Strikingly, this could be abrogated by extracellular TNIP1 protein. This effect would have had to be through an unknown mechanism versus characterized intracellular signaling repression by TNIP1. There is no known or predicted cell-penetrating peptide-like region for cellular reentry of TNIP1. Other reports and our publications established cytoplasmic and nuclear compartmentalization for TNIP1 from endogenous and transfected cDNA expression studies [12, 43]. Nevertheless, the studies establishing the TNIP1-SSc genetic association and/or the reduced TNIP1 expression levels in SSc samples [17, 18, 127, 142] are consistent with and supportive of TNIP1 as a key suppressor of pathways driving a fibrotic signaling whether intrinsic to the fibroblast or in a paracrine fashion where TNIP1 deficiency or defective function in associated epithelial cell (e.g., skin keratinocytes) could make these otherwise protective cells a source of fibroblast-activating cytokines.

5. TNIP1 in Autoimmunity: Summary

Based on the studies of TNIP1 deficiency across a broad spectrum of cell types, including immune cells (DCs, B cells, and T cells) and nonimmune cells (keratinocytes and fibroblasts), it is clear that the loss of TNIP1 expression through knockout or knock-in functional mutations leads to a predisposition for development of autoimmunity. GWAS studies predict this predisposition in human populations through multiple recognized SNPs in TNIP1 genes in patients with autoimmune diseases. Not only does TNIP1 loss or deficiency promotes a hyperinflammatory state, this phenotype closely mimics autoimmune diseases present in human populations. Because of this, manipulation of TNIP1 expression or function can be a useful tool in modeling autoimmunity in mice for the development of drugs and therapies. One fundamental question remaining in autoimmune disease pathogenesis is the cause and initiation of the disease. Through the TNIP1 autoimmune models, it is clear that the potential for TLR stimulation via microbial invasion, cell damage due to wounding, etc. is the first step in pathogenesis. More specifically, this step is described by an exaggerated stimulation of TLRs due to the loss of negative regulation by TNIP1 downstream of receptor activation. With its key regulatory control over multiple signal initiators or pathways, further research on TNIP1 could advance it from association with several autoimmune diseases to a mechanistic contributor to the pathology, and possibly, ultimately, a therapeutic target.

6. Conclusions and Future Directions

(i)The vast majority of autoimmune diseases does not stem from single gene defects and are likely influenced by multiple genes [143] and environmental factors [144] that can promote body-wide and/or tissue-specific autoinflammatory reactions. From human genetic studies, animal models, and in vitro experiments, it would appear that loss, reduction, or dysfunction TNIP1 has the potential to be one of these defects.(ii)With significant negative side-effects of current autoimmune disease therapies, there is a pressing need to develop safer treatments through research into mechanisms underlying these disorders. As highlighted in this review, TNIP1 protein function, as a repressor of signaling downstream from TLR implicated in several autoimmune diseases, could be a pharmacologic target of new therapies.(iii)While likely relevant to hyperactive inflammatory signaling in several autoimmune diseases, the experimental loss or reduction of TNIP1 presents as its own phenotype and does not fully recapitulate any one specific pathology. Nevertheless, the predisposition towards hyperinflammatory reactions of multiple cell types with defective TNIP1 function is likely to provide advantageous insights to further study of tissue-specific and whole animal autoimmune disease models as well as testing of new anti-inflammatory therapies.

Conflicts of Interest

The authors declare no conflict of interest for this article.

Authors’ Contributions

RS and BJA conceived the review topic and both participated in the literature retrieval, data analysis, and review writing. Both authors read and approved the final content.


Cited published work of the authors was supported in part by prior Pfizer ASPIRE Investigator-Initiated Research and NIH (AR048660) grants (BJA) and Department of Pharmaceutical Science Graduate Student Assistantship (RS). The authors appreciate their discussions with Dr. S. Rudraiah regarding cell-specific signaling. RS is grateful to Dr. A. Hubbard for constructive comments on early writing that contributed to this document.


  1. G. S. Cooper, M. L. K. Bynum, and E. C. Somers, “Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases,” Journal of Autoimmunity, vol. 33, no. 3-4, pp. 197–207, 2009. View at: Publisher Site | Google Scholar
  2. A. Marson, W. J. Housley, and D. A. Hafler, “Genetic basis of autoimmunity,” Journal of Clinical Investigation, vol. 125, no. 6, pp. 2234–2241, 2015. View at: Publisher Site | Google Scholar
  3. US Department of Health and Human Services, NIH progress in autoimmune diseases research, National Institutes of Health, 2005, Publication No. 05-514.
  4. A. Lerner, P. Jeremias, and T. Matthias, “The world incidence and prevalence of autoimmune diseases is increasing,” International Journal of Celiac Disease, vol. 3, no. 4, pp. 151–155, 2015. View at: Publisher Site | Google Scholar
  5. S. J. Walsh and L. M. Rau, “Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States,” American Journal of Public Health, vol. 90, no. 9, pp. 1463–1466, 2000. View at: Google Scholar
  6. P. S. Ramos, L. A. Criswell, K. L. Moser et al., “A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap,” PLoS Genetics, vol. 7, no. 12, article e1002406, 2011. View at: Publisher Site | Google Scholar
  7. S. Jorg, D. A. Grohme, M. Erzler et al., “Environmental factors in autoimmune diseases and their role in multiple sclerosis,” Cellular and Molecular Life Sciences, vol. 73, no. 24, pp. 4611–4622, 2016. View at: Publisher Site | Google Scholar
  8. M. Gutierrez-Arcelus, S. S. Rich, and S. Raychaudhuri, “Autoimmune diseases–connecting risk alleles with molecular traits of the immune system,” Nature Reviews Genetics, vol. 17, no. 3, pp. 160–174, 2016. View at: Publisher Site | Google Scholar
  9. M. D. Rosenblum, I. K. Gratz, J. S. Paw, and A. K. Abbas, “Treating human autoimmunity: current practice and future prospects,” Science Translational Medicine, vol. 4, no. 125, article 125sr1, 2012. View at: Publisher Site | Google Scholar
  10. K. Heyninck, D. de Valck, W. V. Berghe et al., “The zinc finger protein A20 inhibits TNF-induced NF-κB–dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB–inhibiting protein ABIN,” The Journal of Cell Biology, vol. 145, no. 7, pp. 1471–1482, 1999. View at: Publisher Site | Google Scholar
  11. M. Fukushi, J. Dixon, T. Kimura, N. Tsurutani, M. J. Dixon, and N. Yamamoto, “Identification and cloning of a novel cellular protein Naf 1, Nef-associated factor 1, that increases cell surface CD4 expression,” FEBS Letters, vol. 442, no. 1, pp. 83–88, 1999. View at: Publisher Site | Google Scholar
  12. K. Gupta, D. Ott, T. J. Hope, R. F. Siliciano, and J. D. Boeke, “A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions,” Journal of Virology, vol. 74, no. 24, pp. 11811–11824, 2000. View at: Publisher Site | Google Scholar
  13. V. Chandran, “The genetics of psoriasis and psoriatic arthritis,” Clinical Reviews in Allergy & Immunology, vol. 44, no. 2, pp. 149–156, 2013. View at: Publisher Site | Google Scholar
  14. Q. Yang, H. Liu, L. Qu et al., “Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris,” The British Journal of Dermatology, vol. 168, no. 5, pp. 1060–1065, 2013. View at: Publisher Site | Google Scholar
  15. E. Ellinghaus, P. E. Stuart, D. Ellinghaus et al., “Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL,” The Journal of Investigative Dermatology, vol. 132, no. 4, pp. 1133–1140, 2012. View at: Publisher Site | Google Scholar
  16. J. Bowes, G. Orozco, E. Flynn et al., “Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1641–1644, 2011. View at: Publisher Site | Google Scholar
  17. L. Bossini-Castillo, J. E. Martin, J. Broen et al., “Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study,” Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 602–607, 2013. View at: Publisher Site | Google Scholar
  18. Y. Allanore, M. Saad, P. Dieudé et al., “Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis,” PLoS Genetics, vol. 7, no. 7, article e1002091, 2011. View at: Publisher Site | Google Scholar
  19. V. Gateva, J. K. Sandling, G. Hom et al., “A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus,” Nature Genetics, vol. 41, no. 11, pp. 1228–1233, 2009. View at: Publisher Site | Google Scholar
  20. J. W. Han, H. F. Zheng, Y. Cui et al., “Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus,” Nature Genetics, vol. 41, no. 11, pp. 1234–1237, 2009. View at: Publisher Site | Google Scholar
  21. H. Cen, M. Zhou, R. X. Leng et al., “Genetic interaction between genes involved in NF-κB signaling pathway in systemic lupus erythematosus,” Molecular Immunology, vol. 56, no. 4, pp. 643–648, 2013. View at: Publisher Site | Google Scholar
  22. C. F. He, Y. S. Liu, Y. L. Cheng et al., “TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population,” Lupus, vol. 19, no. 10, pp. 1181–1186, 2010. View at: Publisher Site | Google Scholar
  23. A. Kawasaki, S. Ito, H. Furukawa et al., “Association of TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese population: a case-control association study,” Arthritis Research & Therapy, vol. 12, no. 5, p. R174, 2010. View at: Publisher Site | Google Scholar
  24. I. Adrianto, S. Wang, G. B. Wiley et al., “Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 64, no. 11, pp. 3695–3705, 2012. View at: Publisher Site | Google Scholar
  25. L. D. Sun, H. Cheng, Z. X. Wang et al., “Association analyses identify six new psoriasis susceptibility loci in the Chinese population,” Nature Genetics, vol. 42, no. 11, pp. 1005–1009, 2010. View at: Publisher Site | Google Scholar
  26. R. P. Nair, K. C. Duffin, C. Helms et al., “Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways,” Nature Genetics, vol. 41, no. 2, pp. 199–204, 2009. View at: Publisher Site | Google Scholar
  27. L. C. Tsoi, S. L. Spain, J. Knight et al., “Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity,” Nature Genetics, vol. 44, no. 12, pp. 1341–1348, 2012. View at: Publisher Site | Google Scholar
  28. C. F. Kuo, M. J. Grainge, A. M. Valdes et al., “Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families,” JAMA Internal Medicine, vol. 175, no. 9, pp. 1518–1526, 2015. View at: Publisher Site | Google Scholar
  29. E. M. Farber and L. Nall, “The natural history of psoriasis in 5,600 patients,” Dermatologica, vol. 148, no. 1, pp. 1–18, 1974. View at: Publisher Site | Google Scholar
  30. L. A. Hindorff, P. Sethupathy, H. A. Junkins et al., “Potential etiologic and functional implications of genome-wide association loci for human diseases and traits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 23, pp. 9362–9367, 2009. View at: Publisher Site | Google Scholar
  31. R. Hunt, Z. E. Sauna, S. V. Ambudkar, M. M. Gottesman, and C. Kimchi-Sarfaty, “Silent (synonymous) SNPs: should we care about them?” Methods in Molecular Biology, vol. 578, pp. 23–39, 2009. View at: Publisher Site | Google Scholar
  32. A. O. Olarerin-George, L. Anton, Y. C. Hwang, M. A. Elovitz, and J. B. Hogenesch, “A functional genomics screen for microRNA regulators of NF-kappaB signaling,” BMC Biology, vol. 11, no. 1, p. 19, 2013. View at: Publisher Site | Google Scholar
  33. J. Gallagher, J. Howlin, C. McCarthy et al., “Identification of Naf1/ABIN-1 among TNF-α-induced expressed genes in human synoviocytes using oligonucleotide microarrays,” FEBS Letters, vol. 551, no. 1–3, pp. 8–12, 2003. View at: Publisher Site | Google Scholar
  34. M. Imbeault, M. Ouellet, K. Giguere et al., “Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment,” Journal of Virology, vol. 85, no. 5, pp. 2189–2200, 2011. View at: Publisher Site | Google Scholar
  35. I. Gurevich, C. Zhang, P. C. Encarnacao, C. P. Struzynski, S. E. Livings, and B. J. Aneskievich, “PPARγ and NF-κB regulate the gene promoter activity of their shared repressor, TNIP1,” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol. 1819, no. 1, pp. 1–15, 2012. View at: Publisher Site | Google Scholar
  36. B. Tian, D. E. Nowak, M. Jamaluddin, S. Wang, and A. R. Brasier, “Identification of direct genomic targets downstream of the nuclear factor-κB transcription factor mediating tumor necrosis factor signaling,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17435–17448, 2005. View at: Publisher Site | Google Scholar
  37. G. Martin, J. Roy, C. Barat, M. Ouellet, C. Gilbert, and M. J. Tremblay, “Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells,” Journal of Virology, vol. 81, no. 11, pp. 5872–5881, 2007. View at: Publisher Site | Google Scholar
  38. Y. Chen, H. Yan, Z. Song et al., “Downregulation of TNIP1 expression leads to increased proliferation of human keratinocytes and severer psoriasis-like conditions in an imiquimod-induced mouse model of dermatitis,” PloS One, vol. 10, no. 6, article e0127957, 2015. View at: Publisher Site | Google Scholar
  39. V. P. Ramirez, W. Krueger, and B. J. Aneskievich, “TNIP1 reduction of HSPA6 gene expression occurs in promoter regions lacking binding sites for known TNIP1-repressed transcription factors,” Gene, vol. 555, no. 2, pp. 430–437, 2015. View at: Publisher Site | Google Scholar
  40. S. Rudraiah, R. Shamilov, and B. J. Aneskievich, “TNIP1 reduction sensitizes keratinocytes to post-receptor signalling following exposure to TLR agonists,” Cellular Signalling, vol. 45, pp. 81–92, 2018. View at: Publisher Site | Google Scholar
  41. S. Oshima, E. E. Turer, J. A. Callahan et al., “ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development,” Nature, vol. 458, no. 7237, pp. 538–909, 2009. View at: Publisher Site | Google Scholar
  42. S. K. Nanda, R. K. C. Venigalla, A. Ordureau et al., “Polyubiquitin binding to ABIN1 is required to prevent autoimmunity,” The Journal of Experimental Medicine, vol. 208, no. 6, pp. 1215–1228, 2011. View at: Publisher Site | Google Scholar
  43. I. Gurevich, C. Zhang, N. Francis, and B. J. Aneskievich, “TNIP1, a retinoic acid receptor corepressor and A20-binding inhibitor of NF-κB, distributes to both nuclear and cytoplasmic locations,” Journal of Histochemistry & Cytochemistry, vol. 59, no. 12, pp. 1101–1112, 2011. View at: Publisher Site | Google Scholar
  44. I. Gurevich and B. J. Aneskievich, “Liganded RARalpha and RARgamma interact with but are repressed by TNIP1,” Biochemical and Biophysical Research Communications, vol. 389, no. 3, pp. 409–414, 2009. View at: Publisher Site | Google Scholar
  45. A. M. Flores, I. Gurevich, C. Zhang, V. P. Ramirez, T. R. Devens, and B. J. Aneskievich, “TNIP1 is a corepressor of agonist-bound PPARs,” Archives of Biochemistry and Biophysics, vol. 516, no. 1, pp. 58–66, 2011. View at: Publisher Site | Google Scholar
  46. L. Huang, L. Verstrepen, K. Heyninck et al., “ABINs inhibit EGF receptor-mediated NF-κB activation and growth of EGF receptor-overexpressing tumour cells,” Oncogene, vol. 27, no. 47, pp. 6131–6140, 2008. View at: Publisher Site | Google Scholar
  47. L. Catrysse, L. Vereecke, R. Beyaert, and G. van Loo, “A20 in inflammation and autoimmunity,” Trends in Immunology, vol. 35, no. 1, pp. 22–31, 2014. View at: Publisher Site | Google Scholar
  48. K. Heyninck, M. M. Kreike, and R. Beyaert, “Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1,” FEBS Letters, vol. 536, no. 1–3, pp. 135–140, 2003. View at: Publisher Site | Google Scholar
  49. P. C. Evans, H. Ovaa, M. Hamon et al., “Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity,” The Biochemical Journal, vol. 378, no. 3, pp. 727–734, 2004. View at: Publisher Site | Google Scholar
  50. D. L. Boone, E. E. Turer, E. G. Lee et al., “The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses,” Nature Immunology, vol. 5, no. 10, pp. 1052–1060, 2004. View at: Publisher Site | Google Scholar
  51. C. J. Wu, D. B. Conze, T. Li, S. M. Srinivasula, and J. D. Ashwell, “Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation,” Nature Cell Biology, vol. 8, no. 4, pp. 398–406, 2006. View at: Publisher Site | Google Scholar
  52. S. Rahighi, F. Ikeda, M. Kawasaki et al., “Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation,” Cell, vol. 136, no. 6, pp. 1098–1109, 2009. View at: Publisher Site | Google Scholar
  53. H. Zhou, I. Wertz, K. O'Rourke et al., “Bcl10 activates the NF-κB pathway through ubiquitination of NEMO,” Nature, vol. 427, no. 6970, pp. 167–171, 2004. View at: Publisher Site | Google Scholar
  54. C. H. Emmerich, A. Ordureau, S. Strickson et al., “Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 38, pp. 15247–15252, 2013. View at: Publisher Site | Google Scholar
  55. A. Richmond, “Nf-kappa B, chemokine gene transcription and tumour growth,” Nature Reviews Immunology, vol. 2, no. 9, pp. 664–674, 2002. View at: Publisher Site | Google Scholar
  56. C. Mauro, F. Pacifico, A. Lavorgna et al., “ABIN-1 Binds to NEMO/IKKγ and co-operates with A20 in Inhibiting NF-κB,” Journal of Biological Chemistry, vol. 281, no. 27, pp. 18482–18488, 2006. View at: Publisher Site | Google Scholar
  57. A. De, T. Dainichi, C. V. Rathinam, and S. Ghosh, “The deubiquitinase activity of A20 is dispensable for NF-κB signaling,” EMBO Reports, vol. 15, no. 7, pp. 775–783, 2014. View at: Publisher Site | Google Scholar
  58. M. G. Kattah, L. Shao, Y. Y. Rosli et al., “A20 and ABIN-1 synergistically preserve intestinal epithelial cell survival,” The Journal of Experimental Medicine, vol. 215, no. 7, pp. 1839–1852, 2018. View at: Publisher Site | Google Scholar
  59. L. Gao, H. Coope, S. Grant, A. Ma, S. C. Ley, and E. W. Harhaj, “ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling,” Journal of Biological Chemistry, vol. 286, no. 42, pp. 36592–36602, 2011. View at: Publisher Site | Google Scholar
  60. E. Meylan, K. Burns, K. Hofmann et al., “RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation,” Nature Immunology, vol. 5, no. 5, pp. 503–507, 2004. View at: Publisher Site | Google Scholar
  61. M. A. O'Donnell, D. Legarda-Addison, P. Skountzos, W. C. Yeh, and A. T. Ting, “Ubiquitination of RIP1 regulates an NF-κB-independent cell-death switch in TNF signaling,” Current Biology: CB, vol. 17, no. 5, pp. 418–424, 2007. View at: Publisher Site | Google Scholar
  62. S. A. Dziedzic, Z. Su, V. Jean Barrett et al., “ABIN-1 regulates RIPK1 activation by linking Met 1 ubiquitylation with Lys 63 deubiquitylation in TNF-RSC,” Nature Cell Biology, vol. 20, no. 1, pp. 58–68, 2018. View at: Publisher Site | Google Scholar
  63. D. Komander and M. Rape, “The ubiquitin code,” Annual Review of Biochemistry, vol. 81, no. 1, pp. 203–229, 2012. View at: Publisher Site | Google Scholar
  64. S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006. View at: Publisher Site | Google Scholar
  65. C. Yao, J. H. Oh, D. H. Lee et al., “Toll-like receptor family members in skin fibroblasts are functional and have a higher expression compared to skin keratinocytes,” International Journal of Molecular Medicine, vol. 35, no. 5, pp. 1443–1450, 2015. View at: Publisher Site | Google Scholar
  66. C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” Annual Review of Immunology, vol. 20, no. 1, pp. 197–216, 2002. View at: Publisher Site | Google Scholar
  67. D. Tang, R. Kang, C. B. Coyne, H. J. Zeh, and M. T. Lotze, “PAMPs and DAMPs: signal 0s that spur autophagy and immunity,” Immunological Reviews, vol. 249, no. 1, pp. 158–175, 2012. View at: Publisher Site | Google Scholar
  68. I. Botos, D. M. Segal, and D. R. Davies, “The structural biology of Toll-like receptors,” Structure, vol. 19, no. 4, pp. 447–459, 2011. View at: Publisher Site | Google Scholar
  69. H. Kumar, T. Kawai, and S. Akira, “Toll-like receptors and innate immunity,” Biochemical and Biophysical Research Communications, vol. 388, no. 4, pp. 621–625, 2009. View at: Publisher Site | Google Scholar
  70. C. A. Scanga, J. Aliberti, D. Jankovic et al., “Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells,” The Journal of Immunology, vol. 168, no. 12, pp. 5997–6001, 2002. View at: Publisher Site | Google Scholar
  71. O. Takeuchi, K. Hoshino, and S. Akira, “Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection,” The Journal of Immunology, vol. 165, no. 10, pp. 5392–5396, 2000. View at: Publisher Site | Google Scholar
  72. H. von Bernuth, C. Picard, Z. Jin et al., “Pyogenic bacterial infections in humans with MyD88 deficiency,” Science, vol. 321, no. 5889, pp. 691–696, 2008. View at: Publisher Site | Google Scholar
  73. S. C. Lin, Y. C. Lo, and H. Wu, “Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling,” Nature, vol. 465, no. 7300, pp. 885–890, 2010. View at: Publisher Site | Google Scholar
  74. D. Chaudhary, S. Robinson, and D. L. Romero, “Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders,” Journal of Medicinal Chemistry, vol. 58, no. 1, pp. 96–110, 2015. View at: Publisher Site | Google Scholar
  75. A. Kanayama, R. B. Seth, L. Sun et al., “TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains,” Molecular Cell, vol. 15, no. 4, pp. 535–548, 2004. View at: Publisher Site | Google Scholar
  76. F. Tokunaga, S. I. Sakata, Y. Saeki et al., “Involvement of linear polyubiquitylation of NEMO in NF-κB activation,” Nature Cell Biology, vol. 11, no. 2, pp. 123–132, 2009. View at: Publisher Site | Google Scholar
  77. M. Bao and Y. J. Liu, “Regulation of TLR7/9 signaling in plasmacytoid dendritic cells,” Protein & Cell, vol. 4, no. 1, pp. 40–52, 2013. View at: Publisher Site | Google Scholar
  78. M. Yamamoto, S. Sato, H. Hemmi et al., “Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway,” Science, vol. 301, no. 5633, pp. 640–643, 2003. View at: Publisher Site | Google Scholar
  79. J. Siednienko, T. Gajanayake, K. A. Fitzgerald, P. Moynagh, and S. M. Miggin, “Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-β and RANTES production,” The Journal of Immunology, vol. 186, no. 4, pp. 2514–2522, 2011. View at: Publisher Site | Google Scholar
  80. A. Witt and D. Vucic, “Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling,” Cell Death and Differentiation, vol. 24, no. 7, pp. 1160–1171, 2017. View at: Publisher Site | Google Scholar
  81. Z. Jiang, T. W. Mak, G. Sen, and X. Li, “Toll-like receptor 3-mediated activation of NF-κB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-β,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 10, pp. 3533–3538, 2004. View at: Publisher Site | Google Scholar
  82. T. R. Reksten, C. J. Lessard, and K. L. Sivils, “Genetics in Sjögren syndrome,” Rheumatic Diseases Clinics of North America, vol. 42, no. 3, pp. 435–447, 2016. View at: Publisher Site | Google Scholar
  83. A. Sukhov, I. E. Adamopoulos, and E. Maverakis, “Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review,” Clinical Reviews in Allergy & Immunology, vol. 51, no. 1, pp. 87–99, 2016. View at: Publisher Site | Google Scholar
  84. N. Kadowaki, S. Ho, S. Antonenko et al., “Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens,” The Journal of Experimental Medicine, vol. 194, no. 6, pp. 863–870, 2001. View at: Publisher Site | Google Scholar
  85. J. J. Hooks, G. W. Jordan, T. Cupps, H. M. Moutsopoulos, A. S. Fauci, and A. L. Notkins, “Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis,” Arthritis and Rheumatism, vol. 25, no. 4, pp. 396–400, 1982. View at: Publisher Site | Google Scholar
  86. C. Gota and L. Calabrese, “Induction of clinical autoimmune disease by therapeutic interferon-α,” Autoimmunity, vol. 36, no. 8, pp. 511–518, 2003. View at: Publisher Site | Google Scholar
  87. S. Akira and H. Hemmi, “Recognition of pathogen-associated molecular patterns by TLR family,” Immunology Letters, vol. 85, no. 2, pp. 85–95, 2003. View at: Publisher Site | Google Scholar
  88. B. A. Cocca, A. M. Cline, and M. Z. Radic, “Blebs and apoptotic bodies are B cell autoantigens,” The Journal of Immunology, vol. 169, no. 1, pp. 159–166, 2002. View at: Publisher Site | Google Scholar
  89. W. G. J. Degen, G. J. M. Pruijn, J. M. H. Raats, and W. J. van Venrooij, “Caspase-dependent cleavage of nucleic acids,” Cell Death & Differentiation, vol. 7, no. 7, pp. 616–627, 2000. View at: Publisher Site | Google Scholar
  90. M. W. Boule, C. Broughton, F. Mackay, S. Akira, A. Marshak-Rothstein, and I. R. Rifkin, “Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes,” The Journal of Experimental Medicine, vol. 199, no. 12, pp. 1631–1640, 2004. View at: Publisher Site | Google Scholar
  91. T. Lovgren, M. L. Eloranta, U. Bave, G. V. Alm, and L. Ronnblom, “Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1861–1872, 2004. View at: Publisher Site | Google Scholar
  92. P. Decker, H. Singh-Jasuja, S. Haager, I. Kotter, and H. G. Rammensee, “Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation,” The Journal of Immunology, vol. 174, no. 6, pp. 3326–3334, 2005. View at: Publisher Site | Google Scholar
  93. E. Savarese, O. W. Chae, S. Trowitzsch et al., “U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7,” Blood, vol. 107, no. 8, pp. 3229–3234, 2006. View at: Publisher Site | Google Scholar
  94. J. A. Deane, P. Pisitkun, R. S. Barrett et al., “Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation,” Immunity, vol. 27, no. 5, pp. 801–810, 2007. View at: Publisher Site | Google Scholar
  95. D. L. Thibault Flesher, X. Sun, T. W. Behrens, R. R. Graham, and L. A. Criswell, “Recent advances in the genetics of systemic lupus erythematosus,” Expert Review of Clinical Immunology, vol. 6, no. 3, pp. 461–479, 2014. View at: Publisher Site | Google Scholar
  96. J. Zhou, R. Wu, A. A. High et al., “A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 44, pp. E998–1006, 2011. View at: Publisher Site | Google Scholar
  97. C. Lood, H. Tyden, B. Gullstrand et al., “Platelet-derived S100A8/A9 and cardiovascular disease in systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 68, no. 8, pp. 1970–1980, 2016. View at: Publisher Site | Google Scholar
  98. E. A. Korte, D. J. Caster, M. T. Barati et al., “ABIN1 determines severity of glomerulonephritis via activation of intrinsic glomerular inflammation,” The American Journal of Pathology, vol. 187, no. 12, pp. 2799–2810, 2017. View at: Publisher Site | Google Scholar
  99. S. K. Nanda, M. Lopez-Pelaez, J. S. C. Arthur, F. Marchesi, and P. Cohen, “Suppression of IRAK1 or IRAK4 catalytic activity, but not type 1 IFN signaling, prevents lupus nephritis in mice expressing a ubiquitin binding–defective mutant of ABIN1,” The Journal of Immunology, vol. 197, no. 11, pp. 4266–4273, 2016. View at: Publisher Site | Google Scholar
  100. R. T. G'Sell, P. M. Gaffney, and D. W. Powell, “Review: A20-binding inhibitor of NF-κB activation 1 is a physiologic inhibitor of NF-κB: a molecular switch for inflammation and autoimmunity,” Arthritis & Rheumatology, vol. 67, no. 9, pp. 2292–2302, 2015. View at: Publisher Site | Google Scholar
  101. V. P. Ramirez, I. Gurevich, and B. J. Aneskievich, “Emerging roles for TNIP1 in regulating post-receptor signaling,” Cytokine & Growth Factor Reviews, vol. 23, no. 3, pp. 109–118, 2012. View at: Publisher Site | Google Scholar
  102. L. Verstrepen, I. Carpentier, and R. Beyaert, “The biology of A20-binding inhibitors of NF-kappaB activation (ABINs),” Advances in Experimental Medicine and Biology, vol. 809, pp. 13–31, 2014. View at: Google Scholar
  103. J. A. Callahan, G. E. Hammer, A. Agelides et al., “Cutting edge: ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells,” The Journal of Immunology, vol. 191, no. 2, pp. 535–539, 2013. View at: Publisher Site | Google Scholar
  104. C. Y. Lu, P. D. Winterberg, J. Chen, and J. R. Hartono, “Acute kidney injury: a conspiracy of Toll-like receptor 4 on endothelia, leukocytes, and tubules,” Pediatric Nephrology, vol. 27, no. 10, pp. 1847–1854, 2012. View at: Publisher Site | Google Scholar
  105. T. Doetschman, “Influence of genetic background on genetically engineered mouse phenotypes,” in Gene Knockout Protocols, W. Wurst and R. Kühn, Eds., vol. 530 of Methods in Molecular Biology, pp. 423–433, 2009. View at: Publisher Site | Google Scholar
  106. F. O. Nestle, D. H. Kaplan, and J. Barker, “Psoriasis,” New England Journal of Medicine, vol. 361, no. 5, pp. 496–509, 2009. View at: Publisher Site | Google Scholar
  107. S. Kagami, H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt, “Circulating Th17, Th22, and Th1 cells are increased in psoriasis,” The Journal of Investigative Dermatology, vol. 130, no. 5, pp. 1373–1383, 2010. View at: Publisher Site | Google Scholar
  108. F. Capon, P. Di Meglio, J. Szaub et al., “Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis,” Human Genetics, vol. 122, no. 2, pp. 201–206, 2007. View at: Publisher Site | Google Scholar
  109. M. Cargill, S. J. Schrodi, M. Chang et al., “A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes,” American Journal of Human Genetics, vol. 80, no. 2, pp. 273–290, 2007. View at: Publisher Site | Google Scholar
  110. L. van der Fits, S. Mourits, J. S. A. Voerman et al., “Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis,” The Journal of Immunology, vol. 182, no. 9, pp. 5836–5845, 2009. View at: Publisher Site | Google Scholar
  111. S. K. Ippagunta, R. Gangwar, D. Finkelstein et al., “Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip 1 function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 41, pp. E6162–E6171, 2016. View at: Publisher Site | Google Scholar
  112. A. Di Cesare, P. Di Meglio, and F. O. Nestle, “The IL-23/Th17 axis in the immunopathogenesis of psoriasis,” The Journal of Investigative Dermatology, vol. 129, no. 6, pp. 1339–1350, 2009. View at: Publisher Site | Google Scholar
  113. J. A. Cruz, E. E. Childs, N. Amatya et al., “IL-17 signaling triggers degradation of the constitutive NF-κB inhibitor ABIN-1,” ImmunoHorizons, vol. 1, no. 7, pp. 133–141, 2017. View at: Publisher Site | Google Scholar
  114. C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” The Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005. View at: Publisher Site | Google Scholar
  115. L. Grine, L. Dejager, C. Libert, and R. E. Vandenbroucke, “An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17,” Cytokine & Growth Factor Reviews, vol. 26, no. 1, pp. 25–33, 2015. View at: Publisher Site | Google Scholar
  116. M. Pasparakis, I. Haase, and F. O. Nestle, “Mechanisms regulating skin immunity and inflammation,” Nature Reviews Immunology, vol. 14, no. 5, pp. 289–301, 2014. View at: Publisher Site | Google Scholar
  117. D. Pattanaik, M. Brown, B. C. Postlethwaite, and A. E. Postlethwaite, “Pathogenesis of systemic sclerosis,” Frontiers in Immunology, vol. 6, p. 272, 2015. View at: Publisher Site | Google Scholar
  118. S. Bernatsky, L. Joseph, C. A. Pineau, P. Belisle, M. Hudson, and A. E. Clarke, “Scleroderma prevalence: demographic variations in a population-based sample,” Arthritis and Rheumatism, vol. 61, no. 3, pp. 400–404, 2009. View at: Publisher Site | Google Scholar
  119. L. K. Andersen and M. D. P. Davis, “Prevalence of skin and skin-related diseases in the Rochester Epidemiology Project and a comparison with other published prevalence studies,” Dermatology, vol. 232, no. 3, pp. 344–352, 2016. View at: Publisher Site | Google Scholar
  120. C. P. Denton and D. Khanna, “Systemic sclerosis,” The Lancet, vol. 390, no. 10103, pp. 1685–1699, 2017. View at: Publisher Site | Google Scholar
  121. D. Khanna, J. Seibold, J. Goldin, D. P. Tashkin, D. E. Furst, and A. Wells, “Interstitial lung disease points to consider for clinical trials in systemic sclerosis,” Rheumatology, vol. 56, Supplement_5, pp. v27–v32, 2017. View at: Publisher Site | Google Scholar
  122. R. Giacomelli, V. Liakouli, O. Berardicurti et al., “Interstitial lung disease in systemic sclerosis: current and future treatment,” Rheumatology International, vol. 37, no. 6, pp. 853–863, 2017. View at: Publisher Site | Google Scholar
  123. Y. Luo, Y. Wang, Q. Wang, R. Xiao, and Q. Lu, “Systemic sclerosis: genetics and epigenetics,” Journal of Autoimmunity, vol. 41, pp. 161–167, 2013. View at: Publisher Site | Google Scholar
  124. J. E. Martin, L. Bossini-Castillo, and J. Martin, “Unraveling the genetic component of systemic sclerosis,” Human Genetics, vol. 131, no. 7, pp. 1023–1037, 2012. View at: Publisher Site | Google Scholar
  125. B. D. Korman and L. A. Criswell, “Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance,” Current Rheumatology Reports, vol. 17, no. 3, p. 21, 2015. View at: Publisher Site | Google Scholar
  126. S. Bhattacharyya, K. S. Midwood, H. Yin, and J. Varga, “Toll-like receptor-4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma,” Advances in Wound Care, vol. 6, no. 10, pp. 356–369, 2017. View at: Publisher Site | Google Scholar
  127. X. Li, E. J. Ampleford, T. D. Howard et al., “Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases,” Journal of Allergy and Clinical Immunology, vol. 130, no. 4, pp. 861–868.e7, 2012. View at: Publisher Site | Google Scholar
  128. E. López-Isac, L. Bossini-Castillo, C. P. Simeon et al., “A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility,” Arthritis Research & Therapy, vol. 16, no. 1, p. R6, 2014. View at: Publisher Site | Google Scholar
  129. R. G. Marangoni, B. D. Korman, Y. Allanore et al., “A candidate gene study reveals association between a variant of the peroxisome proliferator-activated receptor gamma (PPAR-γ) gene and systemic sclerosis,” Arthritis Research & Therapy, vol. 17, no. 1, p. 128, 2015. View at: Publisher Site | Google Scholar
  130. J. E. Martin, J. C. Broen, F. D. Carmona et al., “Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up,” Human Molecular Genetics, vol. 21, no. 12, pp. 2825–2835, 2012. View at: Publisher Site | Google Scholar
  131. E. Koumakis, M. Giraud, P. Dieude et al., “Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity,” Arthritis and Rheumatism, vol. 64, no. 8, pp. 2746–2752, 2012. View at: Publisher Site | Google Scholar
  132. P. Dieude, M. Guedj, J. Wipff et al., “Association of the TNFAIP3 rs 5029939 variant with systemic sclerosis in the European Caucasian population,” Annals of the Rheumatic Diseases, vol. 69, no. 11, pp. 1958–1964, 2010. View at: Publisher Site | Google Scholar
  133. J. C. A. Broen, L. Bossini-Castillo, L. van Bon et al., “A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators,” Arthritis & Rheumatism, vol. 64, no. 1, pp. 264–271, 2012. View at: Publisher Site | Google Scholar
  134. S. Bhattacharyya and J. Varga, “Endogenous ligands of TLR4 promote unresolving tissue fibrosis: implications for systemic sclerosis and its targeted therapy,” Immunology Letters, vol. 195, pp. 9–17, 2018. View at: Publisher Site | Google Scholar
  135. F. Fang, R. G. Marangoni, X. Zhou et al., “Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor β-dependent fibroblast activation,” Arthritis & Rheumatology, vol. 68, no. 8, pp. 1989–2002, 2016. View at: Publisher Site | Google Scholar
  136. S. Bhattacharyya and J. Varga, “Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis,” Current Rheumatology Reports, vol. 17, no. 1, 2015. View at: Publisher Site | Google Scholar
  137. S. Bhattacharyya, K. Kelley, D. S. Melichian et al., “Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma,” The American Journal of Pathology, vol. 182, no. 1, pp. 192–205, 2013. View at: Publisher Site | Google Scholar
  138. S. Bhattacharyya, Z. Tamaki, W. Wang et al., “FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling,” Science Translational Medicine, vol. 6, no. 232, article 232ra50, 2014. View at: Publisher Site | Google Scholar
  139. S. K. Agarwal, M. Wu, C. K. Livingston et al., “Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts,” Arthritis Research & Therapy, vol. 13, no. 1, p. R3, 2011. View at: Publisher Site | Google Scholar
  140. N. Fullard and S. O’Reilly, “Role of innate immune system in systemic sclerosis,” Seminars in Immunopathology, vol. 37, no. 5, pp. 511–517, 2015. View at: Publisher Site | Google Scholar
  141. S. Bhattacharyya, W. Wang, L. V. D. Graham, and J. Varga, “A20 suppresses canonical Smad-dependent fibroblast activation: novel function for an endogenous inflammatory modulator,” Arthritis Research & Therapy, vol. 18, no. 1, p. 216, 2016. View at: Publisher Site | Google Scholar
  142. A. Milano, S. A. Pendergrass, J. L. Sargent et al., “Molecular subsets in the gene expression signatures of scleroderma skin,” PLoS One, vol. 3, no. 7, article e2696, 2008. View at: Publisher Site | Google Scholar
  143. B. Grimbacher, K. Warnatz, P. F. K. Yong, A. S. Korganow, and H. H. Peter, “The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects,” Journal of Allergy and Clinical Immunology, vol. 137, no. 1, pp. 3–17, 2016. View at: Publisher Site | Google Scholar
  144. A. Vojdani, K. M. Pollard, and A. W. Campbell, “Environmental triggers and autoimmunity,” Autoimmune Diseases, vol. 2014, Article ID 798029, 2 pages, 2014. View at: Publisher Site | Google Scholar

Copyright © 2018 Rambon Shamilov and Brian J. Aneskievich. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1470 Views | 424 Downloads | 6 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.